CNCR vs. NUKZ

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and NUKZ (Range Nuclear Renaissance ETF) are both exchange-traded funds - CNCR is a Health & Biotech Equities fund tracking the Loncar Cancer Immunotherapy Index, while NUKZ is a Energy Equities fund tracking the Range Nuclear Renaissance Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.85%/yr for NUKZ.

Performance

CNCR vs. NUKZ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Range Nuclear Renaissance ETF (NUKZ). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

NUKZ

• 1D: 2.23%
• 1M: 1.39%
• YTD: 16.31%
• 6M: 15.14%
• 1Y: 46.32%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. NUKZ - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
NUKZ Range Nuclear Renaissance ETF	5.29%

CNCR vs. NUKZ - Sectors Allocation Comparison

Sectors	CNCR	NUKZ
Healthcare	96.6%	-
Financial Services	3.3%	-
Basic Materials	-	4.0%
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	12.9%
Industrials	-	45.9%
Real Estate	-	-
Technology	-	1.4%
Utilities	-	35.8%

Return for Risk

CNCR vs. NUKZ — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NUKZ

NUKZ Risk / Return Rank: 46
NUKZ Sharpe Ratio Rank: 45
NUKZ Sortino Ratio Rank: 44
NUKZ Omega Ratio Rank: 39
NUKZ Calmar Ratio Rank: 57
NUKZ Martin Ratio Rank: 44

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. NUKZ - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Range Nuclear Renaissance ETF (NUKZ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	NUKZ	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.57	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	1.81	—

Drawdowns

CNCR vs. NUKZ - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum NUKZ drawdown of -33.03%. Use the drawdown chart below to compare losses from any high point for CNCR and NUKZ.

Drawdown Indicators

	CNCR	NUKZ	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-33.03%	+33.03%
Max Drawdown (1Y) Largest decline over 1 year	—	-16.51%	—
Current Drawdown Current decline from peak	0.00%	-3.11%	+3.11%
Average Drawdown Average peak-to-trough decline	0.00%	-6.01%	+6.01%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	6.54%	—

Volatility

Volatility by Period

	CNCR	NUKZ	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	9.95%	—
Volatility (6M) Calculated over the trailing 6-month period	—	22.02%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	29.61%	-29.61%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	32.67%	-32.67%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	32.67%	-32.67%

CNCR vs. NUKZ - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is lower than NUKZ's 0.85% expense ratio.

Dividends

CNCR vs. NUKZ - Dividend Comparison

CNCR has not paid dividends to shareholders, while NUKZ's dividend yield for the trailing twelve months is around 0.78%.

Position	TTM	2025	2024
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%
NUKZ Range Nuclear Renaissance ETF	0.78%	0.91%	0.09%

Frequently Asked Questions

Which ETF is better, CNCR or NUKZ?

On fees, CNCR is cheaper at 0.79% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or NUKZ?

CNCR is cheaper with a 0.79% expense ratio, compared with 0.85% for NUKZ.

Which ETF pays a higher dividend yield, CNCR or NUKZ?

NUKZ has the higher dividend yield at 0.78%, compared with 0.00% for CNCR.

What is the main difference between CNCR and NUKZ?

CNCR is categorized as Health & Biotech Equities, while NUKZ is Energy Equities. CNCR tracks Loncar Cancer Immunotherapy Index, while NUKZ tracks Range Nuclear Renaissance Index. Their fees differ too: 0.79% for CNCR and 0.85% for NUKZ.